{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T03:15:19Z","timestamp":1793502919148,"version":"4.5.0"},"reference-count":31,"publisher":"The Endocrine Society","issue":"10","license":[{"start":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T00:00:00Z","timestamp":1712880000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Ricerca Corrente"},{"name":"Italian Ministry of Health to Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico","id":[{"id":"https:\/\/ror.org\/0053ctp29","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>After denosumab (Dmab) discontinuation C-terminal telopeptide (CTX) levels increase, bone mineral density (BMD) decreases and multiple vertebral fractures (FX) may occur with relevant impacts on women's health. A sequential therapy with bisphosphonates is recommended, and the European Calcified Tissue Society (ECTS) proposed repeated zoledronate (ZOL) administrations in patients with persistently high CTX levels, although the efficacy of this schedule is unknown. In this retrospective study, we describe BMD changes and FX rate in 52 patients managed according to the ECTS recommendations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We measured CTX levels and administered ZOL after 1 month from Dmab withdrawal (t0). After 6 months (t1), we administered a second ZOL infusion, if CTX levels were \u2265280\u2005ng\/L. BMD changes and FX rate were assessed on average after 17 months from Dmab withdrawal.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Seventy-five percent of patients repeated ZOL infusion. In this group, spine BMD declined significantly (\u22125.5 \u00b1 5.6%), while it remained stable in the group with CTX levels &amp;lt;280\u2005ng\/L (\u22120.1 \u00b1 5.5%, P = 0.008). All fractured patients (9.6%) had received &amp;gt;5 Dmab injections and 2 ZOL infusions. The BMD worsening after Dmab withdrawal was associated with CTX t1 [odds ratio (OR) 2.9, interquartile range (IQR) 1.3-6.6, P = .009] and spine BMD gain during Dmab therapy corrected for the number of Dmab injections (OR 3.0, IQR 1.2-7.2, P = .014). A CTX level at t1 &amp;gt; 212\u2005ng\/L had 100% sensitivity in predicting the BMD loss.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In patients with uncontrolled CTX levels after Dmab withdrawal, 2 ZOL infusions 6 months apart do not prevent BMD loss and FX.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgae224","type":"journal-article","created":{"date-parts":[[2024,4,11]],"date-time":"2024-04-11T18:29:35Z","timestamp":1712860175000},"page":"e1817-e1826","source":"Crossref","is-referenced-by-count":43,"title":["Zoledronate After Denosumab Discontinuation: Is Repeated Administrations More Effective Than Single Infusion?"],"prefix":"10.1210","volume":"109","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7236-0713","authenticated-orcid":false,"given":"Giorgia","family":"Grassi","sequence":"first","affiliation":[{"name":"Endocrine Unit, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico , 20122 Milan , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Ghielmetti","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences and Community Health, University of Milan , 20100 Milan , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Zampogna","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences and Community Health, University of Milan , 20100 Milan , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7594-3300","authenticated-orcid":false,"given":"Iacopo","family":"Chiodini","sequence":"additional","affiliation":[{"name":"Department of Medical Biotechnology and Translational Medicine, University of Milan , 20100 Milan , Italy"},{"name":"Unit of Endocrinology, ASST Grande Ospedale Metropolitano Niguarda , 20162 Milan , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3988-3616","authenticated-orcid":false,"given":"Maura","family":"Arosio","sequence":"additional","affiliation":[{"name":"Endocrine Unit, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico , 20122 Milan , Italy"},{"name":"Department of Clinical Sciences and Community Health, University of Milan , 20100 Milan , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9065-3886","authenticated-orcid":false,"given":"Giovanna","family":"Mantovani","sequence":"additional","affiliation":[{"name":"Endocrine Unit, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico , 20122 Milan , Italy"},{"name":"Department of Clinical Sciences and Community Health, University of Milan , 20100 Milan , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Eller-Vainicher","sequence":"additional","affiliation":[{"name":"Endocrine Unit, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico , 20122 Milan , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2024,4,13]]},"reference":[{"issue":"7","key":"2024091609281288300_dgae224-B1","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"2024091609281288300_dgae224-B2","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nrd3705","article-title":"Bench to bedside: elucidation of the OPG\u2013RANK\u2013RANKL pathway and the development of denosumab","volume":"11","author":"Lacey","year":"2012","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"2024091609281288300_dgae224-B3","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1007\/s00198-017-3919-1","article-title":"Observations following discontinuation of long-term denosumab therapy","volume":"28","author":"McClung","year":"2017","journal-title":"Osteoporos Int"},{"issue":"4","key":"2024091609281288300_dgae224-B4","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1210\/jc.2010-1502","article-title":"Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass","volume":"96","author":"Bone","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2024091609281288300_dgae224-B5","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00198-017-4242-6","article-title":"Significant bone loss after stopping long-term denosumab treatment: a post FREEDOM study","volume":"29","author":"Zanchetta","year":"2018","journal-title":"Osteoporos Int"},{"issue":"2","key":"2024091609281288300_dgae224-B6","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/jbmr.3337","article-title":"Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension","volume":"33","author":"Cummings","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"11","key":"2024091609281288300_dgae224-B7","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1002\/jbmr.4705","article-title":"Multiple vertebral fractures after denosumab discontinuation: FREEDOM and FREEDOM extension trials additional post hoc analyses","volume":"37","author":"Cosman","year":"2022","journal-title":"J Bone Miner Res"},{"issue":"5","key":"2024091609281288300_dgae224-B8","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41584-023-00935-3","article-title":"Mechanisms underlying the long-term and withdrawal effects of denosumab therapy on bone","volume":"19","author":"Ferrari","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"2024091609281288300_dgae224-B9","doi-asserted-by":"crossref","first-page":"116498","DOI":"10.1016\/j.bone.2022.116498","article-title":"Effects of zoledronate on bone mineral density and bone turnover after long-term denosumab therapy: observations in a real-world setting","volume":"163","author":"Everts-Graber","year":"2022","journal-title":"Bone"},{"issue":"3","key":"2024091609281288300_dgae224-B10","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1530\/EJE-21-0157","article-title":"Bisphosphonates after denosumab withdrawal reduce the vertebral fractures incidence","volume":"185","author":"Grassi","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"2024091609281288300_dgae224-B11","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1002\/jbmr.3962","article-title":"A single infusion of zoledronate in postmenopausal women following denosumab discontinuation results in partial conservation of bone mass gains","volume":"35","author":"Everts-Graber","year":"2020","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2024091609281288300_dgae224-B12","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1210\/clinem\/dgaa756","article-title":"Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS","volume":"106","author":"Tsourdi","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2024091609281288300_dgae224-B13","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1002\/jbmr.3853","article-title":"Zoledronate for the prevention of bone loss in women discontinuing denosumab treatment. a prospective 2-year clinical trial","volume":"34","author":"Anastasilakis","year":"2019","journal-title":"J Bone Miner Res"},{"issue":"10","key":"2024091609281288300_dgae224-B14","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1002\/jbmr.4098","article-title":"Treatment with zoledronate subsequent to denosumab in osteoporosis: a randomized trial","volume":"35","author":"S\u00f8lling","year":"2020","journal-title":"J Bone Miner Res"},{"issue":"9","key":"2024091609281288300_dgae224-B15","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/jbmr.5650080915","article-title":"Vertebral fracture assessment using a semiquantitative technique","volume":"8","author":"Genant","year":"1993","journal-title":"J Bone Miner Res"},{"issue":"9","key":"2024091609281288300_dgae224-B16","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1007\/s00198-008-0832-7","article-title":"Spinal deformity index (SDI) is a good predictor of incident vertebral fractures","volume":"20","author":"Kerkeni","year":"2009","journal-title":"Osteoporos Int"},{"issue":"9999","key":"2024091609281288300_dgae224-B17","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","article-title":"Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-switch study): extension of a randomised controlled trial","volume":"386","author":"Leder","year":"2015","journal-title":"Lancet"},{"issue":"7","key":"2024091609281288300_dgae224-B18","doi-asserted-by":"crossref","first-page":"e10512","DOI":"10.1002\/jbm4.10512","article-title":"Skeletal responses to romosozumab after 12 months of denosumab","volume":"5","author":"McClung","year":"2021","journal-title":"JBMR Plus"},{"issue":"5","key":"2024091609281288300_dgae224-B19","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/jbmr.4259","article-title":"Efficacy of zoledronic acid in maintaining areal and volumetric bone density after combined denosumab and teriparatide administration: DATA-HD study extension","volume":"36","author":"Ramchand","year":"2020","journal-title":"J Bone Miner Res"},{"issue":"6","key":"2024091609281288300_dgae224-B20","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1007\/s00774-020-01126-w","article-title":"Zoledronic acid sequential therapy could avoid disadvantages due to the discontinuation of less than 3-year denosumab treatment","volume":"38","author":"Kondo","year":"2020","journal-title":"J Bone Miner Metab"},{"issue":"1","key":"2024091609281288300_dgae224-B21","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00223-018-0404-6","article-title":"Bone loss after romosozumab\/denosumab: effects of bisphosphonates","volume":"103","author":"Horne","year":"2018","journal-title":"Calcif Tissue Int"},{"issue":"1","key":"2024091609281288300_dgae224-B22","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s00198-011-1780-1","article-title":"Final results of the DAPS (denosumab adherence preference satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women","volume":"23","author":"Freemantle","year":"2012","journal-title":"Osteoporos Int"},{"issue":"3","key":"2024091609281288300_dgae224-B23","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s00198-022-06648-9","article-title":"Bone loss after denosumab discontinuation is prevented by alendronate and zoledronic acid but not risedronate: a retrospective study","volume":"34","author":"Tutaworn","year":"2023","journal-title":"Osteoporos Int"},{"issue":"10","key":"2024091609281288300_dgae224-B24","doi-asserted-by":"crossref","first-page":"e4155","DOI":"10.1210\/clinem\/dgab321","article-title":"The duration of denosumab treatment and the efficacy of zoledronate to preserve bone mineral density after its discontinuation","volume":"106","author":"Makras","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"2024091609281288300_dgae224-B25","doi-asserted-by":"crossref","first-page":"116764","DOI":"10.1016\/j.bone.2023.116764","article-title":"Maintenance of bone resorption markers in the low premenopausal range during the year following denosumab discontinuation is associated to bone density preservation. The ReoLaus study","volume":"172","author":"Liebich","year":"2023","journal-title":"Bone"},{"issue":"1","key":"2024091609281288300_dgae224-B26","doi-asserted-by":"crossref","first-page":"R19","DOI":"10.1530\/EJE-17-0585","article-title":"DIAGNOSIS OF ENDOCRINE DISEASE: bone turnover markers: are they clinically useful?","volume":"178","author":"Eastell","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"2024091609281288300_dgae224-B27","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1002\/jbmr.3722","article-title":"Relationship between bone mineral density T-score and nonvertebral fracture risk over 10 years of denosumab treatment","volume":"34","author":"Ferrari","year":"2019","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2024091609281288300_dgae224-B28","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s11914-022-00771-6","article-title":"Denosumab discontinuation","volume":"21","author":"S\u00f8lling","year":"2023","journal-title":"Curr Osteoporos Rep"},{"issue":"10","key":"2024091609281288300_dgae224-B29","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1007\/s00198-017-4140-y","article-title":"Effect of denosumab on trabecular bone score in postmenopausal women with osteoporosis","volume":"28","author":"McClung","year":"2017","journal-title":"Osteoporos Int"},{"issue":"3","key":"2024091609281288300_dgae224-B30","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.jocd.2022.03.001","article-title":"Bone mass gains after one denosumab injection followed by zoledronate","volume":"25","author":"Everts-Graber","year":"2022","journal-title":"J Clin Densitom"},{"issue":"3","key":"2024091609281288300_dgae224-B31","doi-asserted-by":"crossref","first-page":"165","DOI":"10.23736\/S0391-1977.20.03137-5","article-title":"Suboptimal medication adherence may favor the progression of vertebral fractures in women with post-menopausal osteoporosis treated with denosumab","volume":"45","author":"Betella","year":"2020","journal-title":"Minerva Endocrinol"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgae224\/58379639\/dgae224.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/109\/10\/e1817\/59135895\/dgae224.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/109\/10\/e1817\/59135895\/dgae224.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T05:30:59Z","timestamp":1726464659000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/109\/10\/e1817\/7645059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,13]]},"references-count":31,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,4,13]]},"published-print":{"date-parts":[[2024,9,16]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgae224","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,10]]},"published":{"date-parts":[[2024,4,13]]}}}